ABC Pharma Competitors

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.

CorePharma is a leading U.S.-based contract development and manufacturing organization (CDMO), dedicated to delivering high-quality pharmaceuticals across diverse therapeutic categories. We provide comprehensive, end-to-end solutions—from early-stage drug development to commercial launch and beyond. With a proven track record of regulatory excellence, CorePharma operates 4 state-of-the-art, FDA- and DEA-registered facilities, spanning 150,000 square feet. Our advanced development, analytical, clinical, and commercial manufacturing and packaging capabilities support an annual production capacity of 5 billion dosage units. Backed by industry-leading lead times, we accelerate your journey from the lab to the clinic—and ultimately to the patient. At CorePharma, we are committed to being your concept to commercial CDMO platform for success.

GENESIS Pharma is a European biopharmaceutical company specializing in the commercialization of innovative pharmaceutical products for serious and rare diseases. Established in 1997, GENESIS Pharma was the first pharmaceutical company in Greece and one of the first in Europe to focus on the sales, marketing and distribution of biopharmaceutical products. Shortly after its founding, the company began to steadily expand at a regional level, currently covering 24 countries in Europe. The robust network of its strategic partnerships comprises leading international pharmaceutical companies dedicated to cutting-edge R&D, alongside fast-growing biopharmaceutical companies with pioneering research and disruptive innovations in the development of targeted, specialized treatments for orphan diseases. In total, GENESIS Pharma holds a product portfolio covering over 30 serious and rare diseases.